DELIVERING BREAKTHROUGHS
Path to Progress
Novel AAV capsids born from Voyager’s RNA-driven TRACERTM screening platform hold promise to target desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional AAV serotypes. TRACER capsids power internal product development and external partnerships with the goal of elevating the field of gene therapy to its highest potential.1
Equipped for the Journey
We see each step in our journey as progress toward unlocking the full potential of gene therapy. This is an opportunity to evolve, innovate, and close in on this breakthrough that has enormous promise to change the trajectory of disease and positively alter the lives of millions of people.
1 Nonnenmacher, et al. “RNA-driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous System.” ASGCT 2021.
In the News
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
Pipeline prioritizes tau antibody for Alzheimer’s disease and gene therapies for GBA1 Parkinson’s disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting development candidate selection for priority programs in 2022 and H1 2023 Cross species transduction for
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose Research presented at the Alzheimer’s Association International Conference CAMBRIDGE, Mass. , Aug.
